



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re application of: Berger *et al.*

Application No. 09/936,702

Filed: September 13, 2001

Confirmation No. 9274

For: A NOVEL CHIMERIC PROTEIN FOR
PREVENTION AND TREATMENT OF
HIV INFECTION

Examiner: Robert A. Zeman

Art Unit: 1645

Attorney Reference No. 4239-60771-01

MAIL STOP RCE
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(4)

Listed on the accompanying form PTO-1449 and enclosed herewith is an English-language document. Applicants respectfully request that this document be listed as a reference cited on the issued patent.

Applicants are filing this Information Disclosure Statement (“IDS”) along with a Request for Continued Examination. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, deposit account authority is provided on the accompanying transmittal letter.


The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Anne Carlson
Anne Carlson, Ph.D.
Registration No. 47,472

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-60771-01
Application Number	09/936,702
Filing Date	September 13, 2001
First Named Inventor	Berger
Art Unit	1645
Examiner Name	Robert A. Zeman

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.